

Paul Da Silva Jardine, PhD

Paul joined Pfizer Central Research in Groton, CT as a Research Chemist in Cardiovascular in 1989. He led the Cardiovascular and Metabolic Diseases Chemistry group until 2009. After that he was appointed Vice President in Diabetes and Cardiovascular Research Unit at Pfizer, responsible for the discovery and development of new medicines from target to Proof of Concept in Phase 2. His teams have been responsible for the discovery and development of over 80 clinical drug candidates one of which was approved in Europe and several were advanced to Phase III development.